Clinical and pharmacological problems in implementation of clinical recommendations on the treatment of community acquired pneumonia
- Authors: Tsyganko D.V1, Berdnikova N.G1,2, Krasnykh L.M3, Politkina S.N3, Klimova O.Y.2, Antonovskiy Y.A1
-
Affiliations:
- City Clinical Hospital n.a. I.V. Davydovsky
- I.M. Sechenov First Moscow State Medical University
- Scientific Centre for Expert Evaluation of Medicinal Products
- Issue: Vol 26, No 11 (2019)
- Pages: 21-29
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312268
- DOI: https://doi.org/10.18565/pharmateca.2019.11.21-29
- ID: 312268
Cite item
Abstract
Full Text
About the authors
D. V Tsyganko
City Clinical Hospital n.a. I.V. Davydovsky
N. G Berdnikova
City Clinical Hospital n.a. I.V. Davydovsky; I.M. Sechenov First Moscow State Medical UniversityPhD, Associate Professor at the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
L. M Krasnykh
Scientific Centre for Expert Evaluation of Medicinal Products
S. N Politkina
Scientific Centre for Expert Evaluation of Medicinal Products
O. Yu Klimova
I.M. Sechenov First Moscow State Medical University
Yu. A Antonovskiy
City Clinical Hospital n.a. I.V. Davydovsky
References
- Charles PG., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respirator or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375-84.
- Чучалин А.Г. Синопальников А.И. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. 2010. URL: http://www.antibiotic.ru/cmac/ pdf/8_1_054.pdf
- Чучалин А.Г. Синопальников А.И. Козлов Р.С. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольнич-ной пневмонии. Пульмонология. 2014;4:13-48. doi: 10.18093/0869-0189-2014-0-4-13-482014. doi: 10.18093/0869-0189-2014-0-4-13-482014.
- Фесенко О.В., Синопальников А.И. Современные системы оценки внебольничной пневмонии тяжелого лечения: перспективы и ограничения. Клиническая микробиология и антимикробная терапия. 2011;3(13):204-13.
- Дворецкий Л.И. Пневмонии у сложных больных. Трудный пациент. 2010. URL: http://t-pacient.ru/ articles/6548/
- Muthu J., Muthanandam S., Mahendra J. Mouth the mirror of lungs: where does the connection lie? Front Med. 2016;10(4):405-9.
- Момот АП, Балацкая И.В., Мартыненко Т. И. и др. Показатели воспалительных реакций, гемостаза и эндотелиоза при тяжелой пневмонии в зависимости от исходов заболевания и их сопряжение. Современные проблемы науки и образования. 2014;2.
- Anderson R., Feldman C. Review manuscript: Mechanisms of platelet activation by the pneumococcus and the role of platelets in community-acquired pneumonia. J. Infect. 2017. pii: S0163-4453(17)30305-5. Doi: 10.1016/j. jinf.2017.09.013.
- Shenoy A.T., Brissac T., Gilley R.P. Streptococcus pneumoniae in the heart subvert the host response through biofilm-mediated resident macrophage killing. PLoS Pathog. 2017;13(8):e1006582.
- Kothe H., Bauer T., Marre R., et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J. 2008;32(1):139-46.
- Mullerova H., Chigbo C., Hagan G.W., et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124-33. Doi: 10.1016/j. rmed.2012.04.008.
- Torres A., Peetermans W.E., Viegi G., Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a lterature review. Thorax. 2013;68(11):1057-65. Doi: 10.1136/ thoraxjnl-2013-204282.
- Almirall J., Boll bar I., Serra-Prat M., et al. Community-Acquired Pneumonia in Catalan Countries (PACAP) Study Group. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur. Respir. J. 2008;31(6):1274-84. doi: 10.1183/09031936.00095807.
- Lai S.W., Lin C.L., Liao K.F. Risk of pneumonia among patients with splenectomy: a retrospective population-based cohort study. Ann. Saudi Med. 2017;37(5):351-56.
- Yan L., Qing Y., Xingyi J., Hongbo Q. Etiologic diagnosis and clinical treatment of multiple drug-resistant bacteria infection in elderly patients with stroke-associated pneumonia after neurosurgery. Cell Biochem. Biophys. 2015;71(2):731-34.
- Shim R., Wong C. Ischemia, Immunosuppression and Infection - Tackling the Predicaments of Post-Stroke Complications. J. Mol Sci. 2016;17(1):64.
- Slinin Y, Foley R.N., Collins A.J. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006;70(6):1135-41.
- Программа СКАТ при оказании стационарной медицинской помощи. Методические рекомендации. 2016. URL: http://www.antimicrob.net/
- Овчинникова Е.А., Овчинникова Л.К. Основные механизмы развития неблагоприятных побочных реакций. Качественная клиническая практика. 2004;1:57-66.
- Рафальский В.В. Нежелательные лекарственные реакции и взаимодействия при антибиотикоте-рапии при инфекции мочевыводящих путей. Методическое пособие. URL: http://www.antibiotic. ru/rus/all/metod/nlr/
- Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2): 512-21.
- Leise M.D., Poterucha J.J., Talwalkar J.A. Drug-induced liver injury. Mayo Clin. Proc. 2014;89(1): 95-106. doi: 10.1016/j.mayocp.2013.09.016.
- Pichichero M.E., Casey J.R. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol. Head Neck Surg. 2007;136(3):340-47.
- Wargo K.A., Edwards J.D. Aminoglycoside-induced nephrotoxicity. J. Pharm. Pract. 2014;27(6):573-77. doi: 10.1177/0897190014546836.
- Tuon FF, Rigatto M.H., Lopes C.K., et al. Risk factors for acute kidney injury in patients treated with polymyxin B. or colistin methanesulfonate sodium. Int. J. Antimicrob. Agents. 2014;43(4):349-52. doi: 10.1016/j.ijantimicag.2013.12.002.
- Poluzzi E., Raschi E., Motola D. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System Drug Saf. 2010;33(4):303-14.
- Owens R.C. Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs. 2004;64(10):1091-124.
- Owens R.C. Jr., Nolin T.D. Antimicrobial-associated QT interval prolongation: pointes of interest. CUn Infect Dis. 2006;43(12):1603-11.
- Goolsby T.A., Jakeman B., Gaynes R.P Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. Int J Antimicrob Agents. 2017. pii: S0924-8579(17)30332-1. doi: 10.1016/j.ijantimicag.2017.08.033.
- Ilgin S., Can O.D., Atli O. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods. 2015;25(5):374-81. doi: 10.3109/15376516. 2015.1026008.
- Granowitz E.V, Brown R.B. Antibiotic adverse reactions and drug interactions. Crit Care Clin. 2008;24(2):421-42. Doi: 10.1016/j. ccc.2007.12.011.
- Mandell L. First international Moxifloxacin symposium. Berlin, 1999. Р 134-38.
- Клиническая фармакокинетика / Под ред. В.Г. Кукеса. М., 2009. C. 406-25. [Clinical pharmacokinetics. Ed. by V.G. Kukes. M., 2009. P. 406-25. (In Russ.)].
- https://www.drugs.com/
- Tokimatsu I., Shigemura K., Kotaki T., et al. A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. Intern Med. 2017;56(11):1315-19.
- Fish D.N., Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997; 32(2):101-19.
- Pal D., Mitra A.K. MDR- and CYP3A4-mediateddrug-drug interactions. 2006;1(3):323-39.
- Varma M.V, Sateesh K., Panchagnula R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm. 2005;2(1):12-21.